Drug Profile
Genz 78132
Alternative Names: D-treo-et-P4Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Glucosylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fabry's disease; Gaucher's disease
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Fabry's disease in USA (PO)
- 04 May 2006 No development reported - Preclinical for Gaucher's disease in USA (PO)
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation